Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...
Posted by Michael Wonder on 17 Jan 2023
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
16 January 2023 - Pharmaceutical manufacturers in Canada often enter into product listing agreements, particularly with public payers, to facilitate their ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 29 Nov 2022
NICE’s new methods: putting innovation first, but at what cost?
28 November 2022 - Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative ...
Posted by Michael Wonder on 23 Aug 2022
The EU HTA regulation: a new frontier for access to innovative technologies
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...
Posted by Michael Wonder on 28 Jun 2022
The Innovative Medicines Fund - good news for patients but has an opportunity been missed to be more ambitious?
27 June 2022 - NHS England and Improvement has announced the launch of the Innovative Medicines Fund. The ABPI’s Director ...
Posted by Michael Wonder on 15 Jun 2022
Shionogi signs agreement with NHS England to begin an innovative subscription payment model for reimbursement of its antibiotic, Fetcroja (cefiderocol)
15 June 2022 - Shionogi recognises the UK’s leadership role in introducing the world’s first fully ‘delinked’ pilot reimbursement model; pull ...
Posted by Michael Wonder on 15 Jun 2022
England’s Innovative Medicines Fund hits another milestone
15 June 2022 - Just like the Cancer Drugs Fund, the time-limited fund for the most promising cancer drugs introduced ...
Posted by Michael Wonder on 22 Jul 2021
NHS England unveils new Innovative Medicine Fund
21 July 2021 - NHS England has unveiled its new Innovative Medicines Fund, to ensure patients have early access to ...
Posted by Michael Wonder on 19 Apr 2021
NICE launches ambitious strategy to provide quicker access to new treatments and innovations
19 April 2021 - NICE will transform key elements of its approach to ensure efficiency and speed while maintaining robust, trusted ...
Posted by Michael Wonder on 30 Mar 2021
NICE methods and process review aims to create fertile ground for innovation
29 March 2021 - The way NICE reviews new medicines is about to go through its biggest change in years – ...
Posted by Michael Wonder on 02 Nov 2020
On the integration of early health technology assessment in the innovation process: reflections from five stakeholders
28 October 2020 - Early health technology assessment, which includes all methods used to inform industry and other stakeholders about the ...
Posted by Michael Wonder on 20 Oct 2020
Health charities and patient groups join together to protect access to breakthrough medical treatments in Canada
19 October 2020 - Patients shut out of process leading to the release of revised guidelines by the Patented Medicine Prices ...
Posted by Michael Wonder on 14 Oct 2020
Evidence for HTA: innovative methods for challenging times
13 October 2020 - Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate explains NICE’s role as co-host of ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...